 Mesenchymal stem cells, MSCs, are promising candidates for regenerative medicine due to their ability to differentiate into various types of cells and their immunomodulatory properties. Despite their potential benefits, there is still debate about whether they can be used as a viable treatment option for cancer. Recent research has demonstrated both positive and negative effects of MSCs on cancer cells, suggesting that further investigation is necessary before considering them as a viable treatment option. Additionally, recent developments in MSC-based drug delivery systems have been made, which could potentially improve the efficacy of existing cancer treatments. This article was authored by Abdo Krimadja, Abdo Krimadja, Alejandro Martin Montalvo, and others.